Chidamide

Phase 3Small molecule

CChipscreen Biosciences, Ltd.

Chidamide is one of 501 small molecule programs targeting Newly Diagnosed. It is currently in Phase 3.

Indications

111

Total Trials

Active Trials

500

Competitors

Pipeline

Status by Indication[3][1]

Indication

Newly DiagnosedUnknown status

TreatmentRecruiting

Peripheral T-Cell LymphomaRecruiting

Leukemia, Myeloid, AcuteRecruiting

Diffuse Large B-Cell Lymphoma(dlbcl)Recruiting

Diffuse Large B-Cell Lymphoma-RecurrentRecruiting

Cutaneous T-Cell Lymphoma (CTCL)Recruiting

T-Cell Acute Lymphoblastic LeukemiaNot yet recruiting

Efficacy and SafetyNot yet recruiting

LymphomaUnknown status

Newly DiagnosedPhase 2

Unknown status

TreatmentPhase 2

Recruiting

Peripheral T-Cell LymphomaPhase 2

Recruiting

Leukemia, Myeloid, AcutePreclinical

Recruiting

Diffuse Large B-Cell Lymphoma(dlbcl)Phase 2

Recruiting

Diffuse Large B-Cell Lymphoma-RecurrentPhase 2

Recruiting

Cutaneous T-Cell Lymphoma (CTCL)Preclinical

Recruiting

T-Cell Acute Lymphoblastic LeukemiaPhase 3

Not yet recruiting

Efficacy and SafetyPhase 2

Not yet recruiting

LymphomaPhase 3

Unknown status

Showing 10 of 26 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Chidamide

CChipscreen Biosciences, Ltd.

Phase 3

7 2

Lexiscan

Astellas

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Acute Monocytic Leukemia

NCT05566054

Q4 2026

N/ARecruiting

Breast Cancer

NCT05890287

Phase 2Not yet recruiting

Colorectal Cancer

NCT06218888

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT06685276

Phase 1/2Recruiting

Recurrence

NCT05682755

Q1 2027

Phase 2Recruiting

Lymphoma

NCT05958719

Clinical

Trials by Indication[1]

Lymphoma31 trials

Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma

Unknown status·SSichuan University·Phase 2·NCT03151876·93 enrolled

Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma

Unknown status·PPeking University·Phase 2·NCT03611231·43 enrolled

Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03630731·32 enrolled

Show 28 more trials

Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma

Unknown status·SSichuan University·Phase 2·NCT03602131·30 enrolled

APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Recruiting· Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.·Phase 1/2·NCT05186012·51 enrolled

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Recruiting·—·Phase 1/2·NCT04337606·100 enrolled

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07339527·60 enrolled

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT02987244·100 enrolled

A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT06087419·42 enrolled

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07139353·54 enrolled

Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Unknown status·SSun Yat-sen University·Phase 2·NCT03321890·102 enrolled

Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma

Unknown status·RRuijin Hospital·Phase 2·NCT02753543·33 enrolled

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT02733380·20 enrolled

Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma

Unknown status·GGuangdong Provincial People's Hospital·Phase 2·NCT02944812·12 enrolled

A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).

Active, not recruiting·TThe First Hospital of Jilin University·Phase 2·NCT06550336·35 enrolled

Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03629873·69 enrolled

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Unknown status·NNanfang Hospital, Southern Medical University·Phase 3·NCT03023358·174 enrolled

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Unknown status·PPeking University·Phase 2·NCT03617432·114 enrolled

Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)

Unknown status·TThe First Affiliated Hospital of Soochow University·N/A·NCT03268889·39 enrolled

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting·SSun Yat-sen University·Phase 1/2·NCT07093710·101 enrolled

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Completed·CChipscreen Biosciences, Ltd.·Phase 1/2·NCT03974243·9 enrolled

Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

Recruiting·SSun Yat-sen University·Phase 2·NCT05572983·47 enrolled

Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

Active, not recruiting·—·Phase 2·NCT06492629·43 enrolled

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Unknown status·—·Phase 2·NCT04233294·100 enrolled

Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)

Unknown status·QQingdao University·Phase 2·NCT03273452·30 enrolled

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Completed·CChipscreen Biosciences, Ltd.·Phase 1·NCT02809573·30 enrolled

Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma

Unknown status·RRuijin Hospital·Phase 2·NCT03853044·23 enrolled

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05958719·37 enrolled

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Terminated·HHenan Cancer Hospital·Phase 1·NCT05083208·12 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

Radiotherapy Combined With GDP With or Without Chidamide in Stage I/II Extranodal Nasal NK/T-cell Lymphoma

Unknown status·CChinese Academy of Medical Sciences·N/A·NCT04511351·76 enrolled

Chidamide7 trials

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03553238·70 enrolled

Chidamide Bridging for CAR-T Therapy

Recruiting·—·Phase 1/2·NCT05370547·120 enrolled

Tofacitinib Combined With Chidamide in R/R ENKTCL

Unknown status·SSichuan University·Phase 2·NCT03598959·20 enrolled

Show 4 more trials

Chidamide Plus R-CHOP in Elderly DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT02753647·49 enrolled

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564704·80 enrolled

Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir

Completed·TTang-Du Hospital·Phase 1/2·NCT02513901·13 enrolled

Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHD

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 1/2·NCT05140616·20 enrolled

Breast Cancer7 trials

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT05890287·60 enrolled

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb Study

Unknown status·—·Phase 1·NCT05586841·30 enrolled

Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib

Unknown status·—·Phase 1/2·NCT05464173·44 enrolled

Show 4 more trials

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Not yet recruiting·—·Phase 2·NCT06556862·155 enrolled

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Recruiting·—·Phase 2·NCT05983107·102 enrolled

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Unknown status·LLiaoning Cancer Hospital & Institute·N/A·NCT05047848·82 enrolled

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Completed·CChipscreen Biosciences, Ltd.·Phase 3·NCT02482753·365 enrolled

Newly Diagnosed4 trials

Sintilimab in Combination With Chidamide in Newly Diagnosed ENKTCL

Unknown status·SSun Yat-sen University·Phase 2·NCT04994210·30 enrolled

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07159620·27 enrolled

Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Recruiting·OOu Bai, MD/PHD·Phase 2·NCT07493148·50 enrolled

Show 1 more trial

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Unknown status·RRuijin Hospital·Phase 2·NCT04480125·28 enrolled

Sintilimab3 trials

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Unknown status·PPeking University·Phase 2·NCT04052659·30 enrolled

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Completed·HHuiqiang Huang·Phase 1/2·NCT03820596·40 enrolled

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Unknown status·SSun Yat-sen University·Phase 2·NCT04831710·83 enrolled

50 more indications

Refractory3 trials

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Enrolling by invitation·SSecond Affiliated Hospital of Soochow University··NCT05690191·169 enrolled

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05823701·23 enrolled

Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL

Unknown status·SSun Yat-sen University·Phase 2·NCT03245905·100 enrolled

Triple-Negative Breast Cancer2 trials

Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

Unknown status·—·Phase 1/2·NCT05747313·40 enrolled

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Unknown status·FFudan University·Phase 2·NCT05438706·70 enrolled

Treatment2 trials

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

Recruiting·TTianjin Medical University Second Hospital·Phase 2·NCT06739395·300 enrolled

Biomarker Guided Treatment in DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT04025593·128 enrolled

Acute Myeloid Leukemia2 trials

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06386302·184 enrolled

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Unknown status·GGe Zheng·Phase 2·NCT05330364·31 enrolled

Maintenance Treatment2 trials

A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT05967949·200 enrolled

Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP

Recruiting·OOu Bai, MD/PHD·Phase 3·NCT07493109·200 enrolled

Metastatic Colorectal Cancer2 trials

Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Recruiting·DDai, Guanghai·Phase 2·NCT06685276·46 enrolled

Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Terminated·TTaipei Medical University Shuang Ho Hospital·Phase 1·NCT05281276·9 enrolled

T-cell acute lymphoblastic leukemia2 trials

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

Completed·ZZhejiang University·Phase 2·NCT05991973·44 enrolled

Chidamide Maintenance to Prevent Relapse After Allogeneic HSCT in Acute T-Lymphoblastic Leukemia/Lymphoma: A Multicenter Randomized Controlled Trial

Not yet recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT07774377·132 enrolled

Peripheral T-Cell Lymphoma2 trials

Multicenter, Single-Arm, Open-Label Clinical Study to Observe the Efficacy of Chidamide Combined With Azacitidine, Prednisone, Cyclophosphamide, and Thalidomide in Patients With Peripheral T-Cell Lymphoma (PTCL) Who Are Intolerant to Standard Chemotherapy.

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07746245·58 enrolled

A Phase II, Open-label, Single-arm, Multicenter Study of Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting·GGreat Novel Therapeutics Biotech & Medicals Corporation·Phase 2·NCT05833724·33 enrolled

Decitabine-primed Tandem CD19/CD20 CAR T Cells1 trial

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Unknown status·—·Phase 1/2·NCT04553393·80 enrolled

Efficacy and Safety1 trial

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled

Induction Therapy1 trial

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06451861·240 enrolled

Nasopharyngeal Carcinoma1 trial

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07320963·52 enrolled

Elderly Patients1 trial

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07415980·68 enrolled

Neuroendocrine Carcinoma1 trial

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05076786·28 enrolled

Relapsed/Refractory AML1 trial

Chidamide Plus DCAG for Relapsed/Refractory AML

Unknown status·—·Phase 1/2·NCT02886559·100 enrolled

Clinical Trial1 trial

A Clinical Trial of Chidamide in the Management of Refractory ITP

Completed·SShandong University·Phase 1/2·NCT03838354·61 enrolled

Immune Checkpoint Inhibitors1 trial

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Unknown status·—·Phase 1/2·NCT05320640·100 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03410004·40 enrolled

Cutaneous T-cell lymphoma1 trial

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04296786·52 enrolled

PD-1antibody1 trial

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Recruiting·RRuijin Hospital·Phase 2·NCT07380984·47 enrolled

Acute Leukemia1 trial

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05951855·42 enrolled

Maintenance Therapy1 trial

Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07304232·134 enrolled

Phase II1 trial

Phase II Umbrella Study Directed by Next Generation Sequencing

Unknown status·GGuangdong Association of Clinical Trials·Phase 2·NCT03574402·400 enrolled

Randomized1 trial

A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP

Unknown status·SShandong University·Phase 2·NCT05411874·100 enrolled

Diagnosis1 trial

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03564470·120 enrolled

Leukemia1 trial

Efficacy and Safety of Chidamide in CBF Leukemia

Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03031262·250 enrolled

Urothelial Carcinoma1 trial

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04562311·45 enrolled

Hepatocellular Carcinoma1 trial

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Terminated·GGreat Novel Therapeutics Biotech & Medicals Corporation·Phase 1/2·NCT05770882·7 enrolled

Non-Small Cell Lung Cancer1 trial

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

Completed·CChipscreen Biosciences, Ltd.·Phase 2·NCT01836679·124 enrolled

Pancreatic Cancer1 trial

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06951997·33 enrolled

Colorectal Cancer1 trial

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06218888·17 enrolled

Angioimmunoblastic T-Cell Lymphoma1 trial

Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05179213·20 enrolled

Carcinoma1 trial

Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety

Unknown status·DDong mei·Phase 2·NCT02883374·30 enrolled

PTCL1 trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Recruiting·DDizal Pharmaceuticals·Phase 3·NCT07234162·218 enrolled

Relapsed/Refractory1 trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Active, not recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 3·NCT04668690·193 enrolled

Conditioning1 trial

Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT

Unknown status·SSichuan University·Phase 2·NCT03336632·50 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Unknown status·SSun Yat-sen University·Phase 2·NCT05008666·37 enrolled

Acute Monocytic Leukemia1 trial

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05566054·92 enrolled

Safety and Efficacy1 trial

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

Completed·UUnited BioPharma·Phase 2·NCT05056974·11 enrolled

Neuroendocrine Neoplasm1 trial

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT05113355·23 enrolled

CHOP1 trial

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Enrolling by invitation·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT05678933·200 enrolled

Dexamethasone1 trial

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

Unknown status·PPeng Liu·Phase 2·NCT03605056·25 enrolled

Recurrence1 trial

Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT

Recruiting·SSichuan University·Phase 1/2·NCT05682755·77 enrolled

Colorectal Carcinoma1 trial

Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04724239·48 enrolled

Advanced NSCLC1 trial

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Completed·CChipscreen Biosciences, Ltd.·Phase 2·NCT05068427·34 enrolled

Epstein Barr Virus1 trial

Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors

Unknown status·SSun Yat-sen University·Phase 2·NCT03494634·66 enrolled

Cutaneous T-cell Lymphoma (CTCL)1 trial

A Prospective Single-Center Phase I/II Clinical Study of Golidocitinib Combined With Chidamide in Patients With Systemically-Treated Cutaneous T-Cell Lymphoma

Recruiting·PPeking Union Medical College Hospital·Preclinical·NCT07754890·65 enrolled

Recruiting·ZZhujiang Hospital·Preclinical·NCT05270200·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 111 trial records for Chidamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chidamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chidamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chipscreen Biosciences, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChipscreen Biosciences, Ltd.

Chidamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Lymphoma31 trials

Chidamide7 trials

Breast Cancer7 trials

Newly Diagnosed4 trials

Sintilimab3 trials

Refractory3 trials

Triple-Negative Breast Cancer2 trials

Treatment2 trials

Acute Myeloid Leukemia2 trials

Maintenance Treatment2 trials

Metastatic Colorectal Cancer2 trials

T-cell acute lymphoblastic leukemia2 trials

Peripheral T-Cell Lymphoma2 trials

Decitabine-primed Tandem CD19/CD20 CAR T Cells1 trial

Efficacy and Safety1 trial

Induction Therapy1 trial

Nasopharyngeal Carcinoma1 trial

Elderly Patients1 trial

Neuroendocrine Carcinoma1 trial

Relapsed/Refractory AML1 trial

Clinical Trial1 trial

Immune Checkpoint Inhibitors1 trial

Diffuse Large B-Cell Lymphoma1 trial

Cutaneous T-cell lymphoma1 trial

PD-1antibody1 trial

Acute Leukemia1 trial

Maintenance Therapy1 trial

Phase II1 trial

Randomized1 trial

Diagnosis1 trial

Leukemia1 trial

Urothelial Carcinoma1 trial

Hepatocellular Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Pancreatic Cancer1 trial

Colorectal Cancer1 trial

Angioimmunoblastic T-Cell Lymphoma1 trial

Carcinoma1 trial

PTCL1 trial

Relapsed/Refractory1 trial

Conditioning1 trial

Induction Chemotherapy1 trial

Acute Monocytic Leukemia1 trial

Safety and Efficacy1 trial

Neuroendocrine Neoplasm1 trial

CHOP1 trial

Dexamethasone1 trial

Recurrence1 trial

Colorectal Carcinoma1 trial

Advanced NSCLC1 trial

Epstein Barr Virus1 trial

Cutaneous T-cell Lymphoma (CTCL)1 trial

Diffuse Large B-Cell Lymphoma-Recurrent1 trial

Diffuse Large B-cell Lymphoma(DLBCL)1 trial

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News